7-Nitroindazole and its rapidly emerging role in opioid pain management and withdrawal
Received 20 March 2012
Accepted for publication 20 March 2012
Published 9 May 2012 Volume 2012:3 Pages 15—16
Richmond, VA, USA
I read with great interest the paper by Jin et al in a recent issue of your journal.1 The article is highly thought-provoking. Interestingly, the past few years have also seen the emergence of nitric oxide synthetase inhibitors, especially 7-nitroindazole, as novel new agents with significant benefits in opioid pain management and withdrawal.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]